vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and AerSale Corp (ASLE). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $90.9M, roughly 1.5× AerSale Corp). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 5.9%, a 29.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -4.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $9.8M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 0.2%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.
ADMA vs ASLE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $90.9M |
| Net Profit | $49.4M | $5.4M |
| Gross Margin | 63.8% | 34.1% |
| Operating Margin | 45.1% | 7.8% |
| Net Margin | 35.5% | 5.9% |
| Revenue YoY | 18.4% | -4.0% |
| Net Profit YoY | -55.9% | 99.7% |
| EPS (diluted) | $0.20 | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $90.9M | ||
| Q3 25 | $134.2M | $71.2M | ||
| Q2 25 | $122.0M | $107.4M | ||
| Q1 25 | $114.8M | $65.8M | ||
| Q4 24 | $117.5M | $94.7M | ||
| Q3 24 | $119.8M | $82.7M | ||
| Q2 24 | $107.2M | $77.1M | ||
| Q1 24 | $81.9M | $90.5M |
| Q4 25 | $49.4M | $5.4M | ||
| Q3 25 | $36.4M | $-120.0K | ||
| Q2 25 | $34.2M | $8.6M | ||
| Q1 25 | $26.9M | $-5.3M | ||
| Q4 24 | $111.9M | $2.7M | ||
| Q3 24 | $35.9M | $509.0K | ||
| Q2 24 | $32.1M | $-3.6M | ||
| Q1 24 | $17.8M | $6.3M |
| Q4 25 | 63.8% | 34.1% | ||
| Q3 25 | 56.3% | 30.2% | ||
| Q2 25 | 55.1% | 32.9% | ||
| Q1 25 | 53.2% | 27.3% | ||
| Q4 24 | 53.9% | 31.4% | ||
| Q3 24 | 49.8% | 28.6% | ||
| Q2 24 | 53.6% | 28.2% | ||
| Q1 24 | 47.8% | 31.8% |
| Q4 25 | 45.1% | 7.8% | ||
| Q3 25 | 38.0% | 4.0% | ||
| Q2 25 | 35.1% | 11.7% | ||
| Q1 25 | 30.4% | -10.1% | ||
| Q4 24 | 32.6% | 5.2% | ||
| Q3 24 | 33.1% | 2.4% | ||
| Q2 24 | 36.6% | -2.4% | ||
| Q1 24 | 26.7% | 5.2% |
| Q4 25 | 35.5% | 5.9% | ||
| Q3 25 | 27.1% | -0.2% | ||
| Q2 25 | 28.1% | 8.0% | ||
| Q1 25 | 23.4% | -8.0% | ||
| Q4 24 | 95.2% | 2.9% | ||
| Q3 24 | 30.0% | 0.6% | ||
| Q2 24 | 29.9% | -4.7% | ||
| Q1 24 | 21.7% | 6.9% |
| Q4 25 | $0.20 | $0.10 | ||
| Q3 25 | $0.15 | $0.00 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.45 | $0.05 | ||
| Q3 24 | $0.15 | $0.01 | ||
| Q2 24 | $0.13 | $-0.07 | ||
| Q1 24 | $0.08 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $4.4M |
| Total DebtLower is stronger | $72.1M | $1.3M |
| Stockholders' EquityBook value | $477.3M | $424.4M |
| Total Assets | $624.2M | $640.5M |
| Debt / EquityLower = less leverage | 0.15× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $4.4M | ||
| Q3 25 | $61.4M | $5.3M | ||
| Q2 25 | $90.3M | $5.7M | ||
| Q1 25 | $71.6M | $4.7M | ||
| Q4 24 | $103.1M | $4.7M | ||
| Q3 24 | $86.7M | $9.8M | ||
| Q2 24 | $88.2M | $4.3M | ||
| Q1 24 | $45.3M | $2.6M |
| Q4 25 | $72.1M | $1.3M | ||
| Q3 25 | $72.4M | $1.5M | ||
| Q2 25 | — | $907.0K | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | $72.3M | $1.2M | ||
| Q3 24 | — | $376.0K | ||
| Q2 24 | — | $522.0K | ||
| Q1 24 | — | $3.5M |
| Q4 25 | $477.3M | $424.4M | ||
| Q3 25 | $431.2M | $417.1M | ||
| Q2 25 | $398.3M | $415.9M | ||
| Q1 25 | $373.4M | $406.5M | ||
| Q4 24 | $349.0M | $455.6M | ||
| Q3 24 | $231.9M | $451.5M | ||
| Q2 24 | $188.3M | $449.8M | ||
| Q1 24 | $153.7M | $452.0M |
| Q4 25 | $624.2M | $640.5M | ||
| Q3 25 | $568.7M | $646.3M | ||
| Q2 25 | $558.4M | $646.7M | ||
| Q1 25 | $510.6M | $646.1M | ||
| Q4 24 | $488.7M | $604.7M | ||
| Q3 24 | $390.6M | $601.5M | ||
| Q2 24 | $376.4M | $598.7M | ||
| Q1 24 | $350.9M | $571.7M |
| Q4 25 | 0.15× | 0.00× | ||
| Q3 25 | 0.17× | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | 0.21× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $11.4M |
| Free Cash FlowOCF − Capex | $34.6M | $9.8M |
| FCF MarginFCF / Revenue | 24.8% | 10.8% |
| Capex IntensityCapex / Revenue | 0.8% | 1.7% |
| Cash ConversionOCF / Net Profit | 0.72× | 2.11× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-29.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $11.4M | ||
| Q3 25 | $13.3M | $-8.9M | ||
| Q2 25 | $21.1M | $19.8M | ||
| Q1 25 | $-19.7M | $-45.2M | ||
| Q4 24 | $50.2M | $37.5M | ||
| Q3 24 | $25.0M | $10.4M | ||
| Q2 24 | $45.6M | $-15.3M | ||
| Q1 24 | $-2.2M | $-21.5M |
| Q4 25 | $34.6M | $9.8M | ||
| Q3 25 | $-1.1M | $-9.8M | ||
| Q2 25 | $18.7M | $18.6M | ||
| Q1 25 | $-24.4M | $-47.6M | ||
| Q4 24 | $47.5M | $32.3M | ||
| Q3 24 | $24.0M | $8.9M | ||
| Q2 24 | $43.6M | $-18.9M | ||
| Q1 24 | $-4.6M | $-25.0M |
| Q4 25 | 24.8% | 10.8% | ||
| Q3 25 | -0.8% | -13.8% | ||
| Q2 25 | 15.3% | 17.3% | ||
| Q1 25 | -21.2% | -72.4% | ||
| Q4 24 | 40.4% | 34.0% | ||
| Q3 24 | 20.0% | 10.7% | ||
| Q2 24 | 40.7% | -24.6% | ||
| Q1 24 | -5.6% | -27.7% |
| Q4 25 | 0.8% | 1.7% | ||
| Q3 25 | 10.7% | 1.3% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 3.7% | ||
| Q4 24 | 2.3% | 5.6% | ||
| Q3 24 | 0.9% | 1.9% | ||
| Q2 24 | 1.9% | 4.7% | ||
| Q1 24 | 2.9% | 3.9% |
| Q4 25 | 0.72× | 2.11× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 2.31× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 13.89× | ||
| Q3 24 | 0.70× | 20.52× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | -3.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
